WARREN, N.J., Feb. 24, 2026 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ: AQST) (“Aquestive” or the “Company”), a pharmaceutical company advancing medicines to bring meaningful improvement to patients' lives through innovative science and delivery technologies, today announced that it will report results for the fourth quarter ended December 31, 2025 and provide an update on recent developments in its business after market close on Wednesday, March 4, 2026. Management will host a conference call ...

When Jeff Bezos said that one breakthrough technology would shape Amazon’s destiny, even Wall Street’s biggest analysts were caught off guard. Fast forward a year and Amazon’s new CEO Andy Jassy described generative AI as a “once-in-a-lifetime” technology that is already being used across Amazon to reinvent customer experiences. At the 8th Future Investment Initiative conference, Elon Musk predicted that by 2040 there would be at least 10 billion humanoid robots, with each priced between $20,000 and $25,000 ...

WARREN, N.J., Feb. 23, 2026 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ:AQST) ("Aquestive" or the "Company"), a pharmaceutical company advancing medicines to bring meaningful improvement to patients' lives through innovative science and delivery technologies, announced today that the management team will participate in the upcoming Oppenheimer 36th Annual Healthcare Life Sciences Conference on February 25-26, which is a virtual event. The Aquestive team will be presenting on February 26th, at 1 ...

Core Viewpoint - Aquestive Therapeutics announced the investigational use of Anaphylm™ (dibutepinephrine) sublingual film, which achieved clinically relevant epinephrine plasma concentrations without causing a dip in diastolic blood pressure, highlighting its potential to transform anaphylaxis management [1][2]. Group 1: Product Details - Anaphylm™ is a polymer matrix-based epinephrine prodrug that is small, lightweight, and dissolves on contact, requiring no water or swallowing for administration [3]. - The product's packaging is designed to be portable and weather-resistant, making it easy to carry in a wallet or phone [3]. - If approved by the FDA, Anaphylm would be the first oral medication for the rescue treatment of severe allergic reactions, including anaphylaxis [3]. Group 2: Clinical Data and Presentations - Multiple poster presentations at the 2026 AAAAI Annual Meeting will showcase the clinical data for Anaphylm, emphasizing its differentiated profile and potential for meaningful outcomes [2]. - Key findings include the absence of a diastolic blood pressure dip following sublingual administration, which is a significant clinical concern in anaphylaxis treatment [2]. Group 3: Company Overview - Aquestive Therapeutics focuses on advancing medicines through innovative science and delivery technologies, operating as both a product developer and a Contract Development and Manufacturing Organization (CDMO) [5]. - The company has a portfolio that includes four commercialized products and a library of over 20 epinephrine prodrugs for various allergy and dermatological indications [5].

Board-certified allergist and leading food allergy and anaphylaxis researcher joins Aquestive to support Anaphylm™ (dibutepinephrine) sublingual film NDA resubmission and pipeline WARREN, N.J., Feb. 18, 2026 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ: AQST) (“Aquestive” or the “Company”), a pharmaceutical company advancing medicines to bring meaningful improvement to patients' lives through innovative science and delivery technologies, today announced the appointment of Matthew Greenhawt, MD, ...

"Great service with in-depth research on biotech stocks. I appreciate that Dr. Sharma will take the time to review and publish reports/updates on stocks that members request. Biotech investing is very complex, and it's great to have someone so knowledgeable guiding us.""The best I have ever seen in the biotech space... I have been in the biotech investing space for a while and have not seen a service like the one Dr. Bhavneesh provides."With a robust academic background including an MBA in Finance from NYU- ...

"Great service with in-depth research on biotech stocks. I appreciate that Dr. Sharma will take the time to review and publish reports/updates on stocks that members request. Biotech investing is very complex, and it's great to have someone so knowledgeable guiding us.""The best I have ever seen in the biotech space... I have been in the biotech investing space for a while and have not seen a service like the one Dr. Bhavneesh provides."With a robust academic background including an MBA in Finance from NYU- ...

Core Viewpoint - Aquestive Therapeutics, Inc. experienced a significant stock decline of approximately 40% following the FDA's identification of deficiencies in its New Drug Application for Anaphylm, raising concerns about the drug's approvability ahead of the PDUFA action date [5]. Group 1: Company Overview - Aquestive Therapeutics, Inc. is a biopharmaceutical company focused on developing innovative therapies for patients with severe allergic reactions [5]. - The company is publicly traded on NASDAQ under the ticker symbol AQST [4]. Group 2: Recent Developments - The FDA has identified deficiencies in the New Drug Application for Anaphylm, which is an experimental sublingual film intended for the treatment of severe allergic reactions, including anaphylaxis [5]. - The deficiencies noted by the FDA currently prevent discussions regarding labeling and post-marketing requirements, which raises concerns about the likelihood of the application being approved by the January 31, 2026 PDUFA action date [5]. Group 3: Legal Implications - Faruqi & Faruqi, LLP is investigating potential claims against Aquestive Therapeutics for investors who suffered significant losses due to the recent stock decline [4][5]. - The law firm has a history of recovering hundreds of millions of dollars for investors since its establishment in 1995 [4].

Core Viewpoint - Aquestive Therapeutics, Inc. experienced a significant stock decline of approximately 40% after the FDA identified deficiencies in its New Drug Application for Anaphylm, raising concerns about the drug's approvability ahead of the January 31, 2026 PDUFA action date [4]. Company Overview - Aquestive Therapeutics, Inc. is a biopharmaceutical company focused on developing innovative therapies for patients with severe allergic reactions, including anaphylaxis [4]. Legal Investigation - Faruqi & Faruqi, LLP, a national securities law firm, is investigating potential claims against Aquestive Therapeutics for investors who suffered significant losses due to the recent stock decline [2][3].

Core Viewpoint - Aquestive Therapeutics, Inc. experienced a significant stock decline of approximately 40% following the FDA's identification of deficiencies in its New Drug Application for Anaphylm, raising concerns about the drug's approvability ahead of the upcoming PDUFA action date on January 31, 2026 [3]. Company Summary - Faruqi & Faruqi, LLP is investigating potential claims against Aquestive Therapeutics due to the recent stock losses [2]. - The firm has a history of recovering hundreds of millions of dollars for investors since its establishment in 1995 [2]. Industry Context - The FDA's feedback on the New Drug Application for Anaphylm indicates significant regulatory hurdles that could impact the company's future product approvals and market performance [3].